Search Strategy
No.	Query	Results
#4	#1 AND #2 AND #3 AND [humans]/lim AND [english]/lim AND [abstracts]/lim AND [1-1-2000]/sd NOT [15-9-2016]/sd	2,191
#3	anthracycline OR daunorubicin OR doxorubicin OR idarubicin OR mitoxantrone OR valrubicin OR capecitabine OR carboplatin OR cetuximab OR cisplatin OR cyclophosphamide OR docetaxel OR epirubicin OR erlotinib OR etoposide OR fluorouracil OR gefitinib OR gemcitabine OR irinotecan OR leucovorin OR mercaptopurine OR methotrexate OR oxaliplatin OR paclitaxel OR radiotherapy OR rituximab OR sunitinib OR tamoxifen OR tegafur OR thioguanine OR trastuzumab OR lapatinib OR panitumumab OR fludarabine OR cladribine OR clofarabine OR nelarabine OR pentostatin OR azacitidine OR cytarabine OR decitabine OR purine OR pyrimidine	1,408,265
#2	‘gene mutation’/exp OR ‘genetics’/exp OR ‘genetic screening’/exp OR ‘single nucleotide polymorphism’/exp OR ‘sequence analysis’/exp OR ‘personalized medicine’/exp OR ‘pharmacogenomics’/exp OR (gene OR genes OR genetic) NEAR/3 (test OR tests OR tested OR testing) OR genomic* OR dna NEAR/3 sequenc* OR pharmacogen* OR (individualized OR individualised OR personalized OR personalised OR precision) NEAR/3 medicine OR single NEAR/3 nucleotide NEAR/3 polymorphism* OR snp OR dpyd OR tpmt OR egfr OR xpc OR mthfr OR gstp1 OR cyp2d6 OR tanc1 OR ugt1a1 OR nqo1 OR slco1b1 OR tyms OR abcb1 OR fcgr3a OR ercc1 OR sod2 OR cbr3 OR ugt1a9 OR c8orf34 OR sema3c OR fcgr2a OR egf OR nt5c2 OR xrcc1 OR dync2h1 OR gstm1 OR kras OR umps OR fastkd3 OR tp53 OR slc28a3 OR mtrr OR has3 OR hla-dqa1 OR nudt15	2,300,474
#1	‘pharmacoeconomics’/exp OR ‘cost effectiveness analysis’/exp OR ‘cost utility analysis’/exp OR ‘cost minimization analysis’/exp OR ‘cost benefit analysis’/exp OR ‘cost control’/exp OR ‘economics’/mj OR pharmacoeconomic* OR health NEAR/3 economic* OR (economic AND evaluation*) OR (economic AND outcome*) OR (analy* NEAR/3 (cost OR costs OR economic*)) OR (cost NEAR/3 (effective* OR benefit OR utility)) OR ‘cost of illness’	693,472
Drug List and Drug Selection
PharmGKB accessed on October 1, 2016. The following cancer treatment-related drug terms were identified through the PharmGKB Clinical Annotations list: Alkylating agents, anthracyclines and related substances, antineoplastic agents, azathioprine, capecitabine, carboplatin, cetuximab, cisplatin, cyclophosphamide, docetaxel, epirubicin, erlotinib, etoposide, fluorouracil, gefitinib, gemcitabine, irinotecan, lapatinib, leucovorin, mercaptopurine, methotrexate, oxaliplatin, paclitaxel, panitumumab, platinum, platinum compounds, purine analogs, pyrimidine analogs, radiotherapy, rituximab, SN-38, sunitinib, tamoxifen, tegafur, thioguanine, trastuzumab. The following cancer drug terms were included in the search term: Anthracycline, daunorubicin, doxorubicin, idarubicin, mitoxantrone, valrubicin, capecitabine, carboplatin, cetuximab, cisplatin, cyclophosphamide, docetaxel, epirubicin, erlotinib, etoposide, fluorouracil, gefitinib, gemcitabine, irinotecan, leucovorin, mercaptopurine, methotrexate, oxaliplatin, paclitaxel, radiotherapy, rituximab, sunitinib, tamoxifen, tegafur, thioguanine, trastuzumab, lapatinib, panitumumab, fludarabine, cladribine, clofarabine, nelarabine, pentostatin, azacitidine, cytarabine, decitabine, purine, pyrimidine. When drug classes were listed, all drugs within that class were included as categorized within PharmGKB. The only time this was not done was for antineoplastic agents and alkylating agents because they are a broad class description. The PharmGKB Clinical Annotations page was checked for antineoplastic agents with respect to gene TP53 mutations, and relevant agents are on the included drug list: Cisplatin, cyclophosphamide, fluorouracil, paclitaxel. PharmGKB Clinical Annotations page was checked for alkylating agents with respect to gene NQO1 mutations and the relevant agent is on the list: cyclophosphamide. PharmGKB lists the following as anthracyclines: Daunorubicin, doxorubicin, idarubicin, mitoxantrone, valrubicin. PharmGKB lists the following as purine analogs: Azathioprine, cladribine, clofarabine, fludarabine, mercaptopurine, nelarabine, thioguanine, pentostatin. Azathioprine is not indicated for cancer treatment and therefore excluded from the list. PharmGKB lists the following as pyrimidine analogs: Azacitidine, capecitabine, cytarabine, decitabine, fluorouracil, gemcitabine, tegafur. PharmGKB lists the following as platinum compounds: Oxaliplatin, carboplatin, cisplatin. Platinum and platinum compounds were not included in the search as only 3 drugs are in this class and inclusion of these terms is redundant. SN-38 is excluded because it is the active metabolite of irinotecan and inclusion would be redundant.